导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -0.79% | 2621/4773 |
| 近一周 | -2.73% | 3213/5458 |
| 近一月 | -6.60% | 3722/5421 |
| 近一季 | -9.52% | 3969/5205 |
| 近半年 | -4.97% | 2865/4920 |
| 近一年 | 2.98% | 2182/4361 |
| 近两年 | 63.42% | 1144/2954 |
| 近三年 | 31.67% | 994/2253 |
| 成立以来 | 96.78% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-0.95% 2030/4961 |
20.06% 1254/5312 |
- - |
- - |
| 2025 | 28.91% 1439/4813 |
0.15% 1965/3635 |
0.33% 2695/4076 |
29.41% 1223/4524 |
-0.87% 2693/4813 |
| 2024 | 10.85% 1368/3463 |
-0.62% 1132/2808 |
-4.26% 1488/3014 |
18.52% 996/3129 |
-1.70% 1799/3463 |
| 2023 | -13.49% 1545/2656 |
5.19% 817/2280 |
-5.05% 1356/2385 |
-7.69% 1611/2515 |
-6.17% 1653/2655 |
| 2022 | -24.59% 1230/2207 |
-17.85% 1272/1919 |
7.18% 515/2016 |
-15.66% 1333/2113 |
1.55% 1228/2208 |
| 2021 | 0.47% 713/1822 |
-4.87% 894/1255 |
9.99% 503/1330 |
-6.48% 938/1466 |
2.67% 539/1822 |
| 2020 | 40.67% 307/1250 |
-4.35% 358/1028 |
20.18% 282/1067 |
8.00% 744/1164 |
13.30% 370/1184 |
| 2019 | 44.14% 178/1092 |
33.93% 126/754 |
-5.38% 466/804 |
3.58% 244/850 |
9.81% 191/918 |
| 2018 | -32.08% 518/834 |
- - |
- - |
- - |
-13.09% 507/691 |
| 2017 | 12.41% 278/714 |
- - |
- - |
- - |
- - |
| 2016 | -18.32% 414/605 |
- - |
- - |
- - |
- - |
| 2015 | 29.04% 80/575 |
- - |
- - |
- - |
- - |
| 2014 | 26.70% 176/237 |
- - |
- - |
- - |
- - |
| 2013 | 4.13% 57/186 |
- - |
- - |
- - |
- - |
| 2012 | 2.54% 94/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇添富深证300ETF联接A VS. 长安沪深300非周期A(740101) |